Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is an aggressive and molecularly heterogeneous non-Hodgkin’s lymphoma. The B cell receptor (BCR) signaling pathway in DLBCL emerges as a new drug target. Protein phosphatase SHP-1 negatively regulates several oncogenic tyrosine kinases and plays a tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ji-Lin, Chu, Pei-Yi, Huang, Chun-Teng, Huang, Tzu-Ting, Wang, Wan-Lun, Lee, Yu-Hsuan, Chang, Yuan-Ya, Dai, Ming-Shen, Shiau, Chung-Wai, Liu, Chun-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358803/
https://www.ncbi.nlm.nih.gov/pubmed/35941532
http://dx.doi.org/10.1186/s10020-022-00518-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358803/
https://www.ncbi.nlm.nih.gov/pubmed/35941532
http://dx.doi.org/10.1186/s10020-022-00518-0

Ejemplares similares